Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Chemoimmunotherapy: reengineering tumor immunity.

Chen G, Emens LA.

Cancer Immunol Immunother. 2013 Feb;62(2):203-16. doi: 10.1007/s00262-012-1388-0. Epub 2013 Feb 7. Review.

2.

Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K.

Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.

3.

Chemoimmunotherapy.

Emens LA.

Cancer J. 2010 Jul-Aug;16(4):295-303. doi: 10.1097/PPO.0b013e3181eb5066. Review.

4.

Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.

Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, Hong YK.

Clin Vaccine Immunol. 2010 Jan;17(1):143-53. doi: 10.1128/CVI.00292-09. Epub 2009 Nov 4.

5.

Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.

Radfar S, Wang Y, Khong HT.

J Immunol. 2009 Nov 15;183(10):6800-7. doi: 10.4049/jimmunol.0901747. Epub 2009 Oct 21.

6.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.

PMID:
21928125
7.

Toward integrative cancer immunotherapy: targeting the tumor microenvironment.

Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J.

J Transl Med. 2012 Apr 10;10:70. doi: 10.1186/1479-5876-10-70.

8.

Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.

Aguilar LK, Guzik BW, Aguilar-Cordova E.

J Cell Biochem. 2011 Aug;112(8):1969-77. doi: 10.1002/jcb.23126. Review.

PMID:
21465529
9.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
10.

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.

Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.

Clin Cancer Res. 2005 Aug 1;11(15):5566-71.

11.

MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.

Chhabra A.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):344-52.

PMID:
19807670
12.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

13.

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA.

PLoS One. 2009 Sep 10;4(9):e6982. doi: 10.1371/journal.pone.0006982.

14.

Targeting the tumor microenvironment by immunotherapy: part 2.

Leibovici J, Itzhaki O, Huszar M, Sinai J.

Immunotherapy. 2011 Nov;3(11):1385-408. doi: 10.2217/imt.11.112. Review.

PMID:
22053888
15.

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.

Lynch DH.

Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Review.

PMID:
18364008
16.

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.

Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF, Wu TC.

Cancer Res. 2013 Apr 15;73(8):2493-504. doi: 10.1158/0008-5472.CAN-12-4241. Epub 2013 Feb 15.

17.

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.

Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM.

Cancer Res. 2005 Dec 15;65(24):11752-61.

19.

Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.

Mashino K, Sadanaga N, Tanaka F, Ohta M, Yamaguchi H, Mori M.

Mol Cancer Ther. 2002 Aug;1(10):785-94.

20.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
Items per page

Supplemental Content

Write to the Help Desk